Left Ventricular Mass and Volume With Telmisartan, Ramipril, or Combination in Patients With Previous Atherosclerotic Events or With Diabetes Mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET])

Left Ventricular Mass and Volume With Telmisartan, Ramipril, or Combination in Patients With Previous Atherosclerotic Events or With Diabetes Mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET])

The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) showed that the angiotensin receptor blocker telmisartan 80 mg was not inferior to the angiotensin-converting enzyme inhibitor ramipril 10 mg, and the combination no more effective than ramipril alone, in...

Full description

Bibliographic Details
Main Authors: Cowan, B., Young, A., Anderson, C., Doughty, R., Krittayaphong, R., Lonn, E., Marwick, T., Reid, Christopher, Sanderson, J., Schmieder, R., Teo, K., Wadham, A., Worthley, S., Yu, C., Yusuf, S., Jennings, G.
Format: Journal Article
Published: Excerpta Medica, Inc 2009
Online Access:http://hdl.handle.net/20.500.11937/6541

Similar Items

Similar Items